newdrugapprovals.org
First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Gains Positive CHMP Opinion for the Treatment of COPD
The developer: Novartis, Vectura Peak projections: $2 billion-$5 billion TOKYO, July 27, 2013 /CNW/ – QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of bot…